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with hormone receptor-positive breast cancer does not 
follow any clear guidelines, and some patients may un-
necessarily undergo chemotherapy and be exposed to the 
associated toxicity. The aim of this study was to identify 
the patient population for whom this issue may bear rele-
vance. Methods: Patients being treated with letrozole in 
the prospective multicenter noninterventional EvAluate-
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TM study were recruited. The percentage of patients re-
ceiving chemotherapy and factors associated with chemo-
therapy administration were identified. Results: In all, 
3,924 (37.4%) patients received chemotherapy before 
treatment with letrozole. Of these, 293 (20%) underwent 
neoadjuvant therapy. Younger age was predictive for 
both adjuvant and neoadjuvant therapy. Overall, deci-
sions in favor of administering chemotherapy are more 
likely to be made in patients with a higher body mass 
index (BMI), and neoadjuvant chemotherapy is adminis-
tered at a higher rate in women with a lower BMI. Con-
comitant medication influenced the overall decision-mak-
ing regarding chemotherapy, irrespective of whether it 
was given on a neoadjuvant or adjuvant basis. Conclu-
sion: There is an ongoing debate as to whether all of the 
many patients who receive chemotherapy actually benefit 
from it. Neoadjuvant chemotherapy is frequently adminis-
tered in this patient population, and this should encour-
age further research to resolve current clinical and re-
search issues.
© 2016 S. Karger GmbH, Freiburg
Introduction
Over the last few decades, chemotherapy has become an estab-
lished treatment for breast cancer patients who have an unfavora-
ble prognosis. In these patients, chemotherapy can improve both 
disease-free survival and overall survival [1]. Treatment decisions 
are mainly based on prognosis, which is assessed using patient and 
tumor characteristics including age, tumor size, nodal status, grad-
ing, estrogen receptor (ER) status, progesterone receptor status, 
and human epidermal growth factor receptor 2 (HER2) status. A 
few tools are available that can help assess the absolute risk of re-
currence on the basis of these factors [2, 3]. However, new evidence 
has recently become available, not only in relation to prognostic 
groups but also predictive factors, pertaining to the fact that the 
same form of treatment does not have the same effects in all pa-
tients with similar classic patient and tumor characteristics.
A great deal has been learned about chemotherapy from studies 
on neoadjuvant treatment. The greatest benefit is seen in patients 
with either triple-negative breast cancer or HER2-positive breast 
cancer [4, 5]. The rates of pathological complete response (pCR) 
are high in these patients, at 30% for HER2-positive and 34% for 
triple-negative breast cancer patients [5]. With these 2 subtypes, 
complete disappearance of the invasive tumor is associated with a 
favorable prognosis. However, patients with hormone receptor-
positive, HER2-negative tumors have been found to have a pCR 
rate of 7.4% if the tumor grade is 1 or 2, and 16% if the grade is 3 
[5]. In these subtypes, it is not clear whether pCR translates into a 
favorable prognosis in the same way as it does in patients with 
HER2-positive or triple-negative breast cancers. Similar data have 
also been reported from other studies [6]. This suggests that in ad-
dition to an unfavorable prognosis, molecular factors may also be 
potential predictors for the efficacy of chemotherapy and its bene-
fit for breast cancer patients, independently of their prognosis.
These findings have also influenced the treatment guidelines for 
breast cancer. In 2003, for example, positive lymph nodes were still 
regarded as an indication for adjuvant chemotherapy [7]. How-
ever, the importance attached to lymph node involvement declined 
over time [8–11], and by 2013, positive lymph node involvement 
on its own was no longer viewed as an absolute indication for 
chemotherapy [12]. In contrast, the importance attached to mo-
lecular factors among the decision-making criteria for or against 
chemotherapy has been increasing [7–14]. Particularly in breast 
cancer patients with hormone receptor-positive tumors it appears 
to be difficult to assess the potential benefit of cytotoxic therapy 
[12]. There have been discussions as to whether factors such as 
Ki-67 and grading may be useful in the decision-making for or 
against chemotherapy. Patients with low Ki-67 values of under 
20%, for example, have been found to have a pCR rate of less than 
10%, while patients with Ki-67 values over 35% have a pCR rate of 
up to 20% [6]. However, Ki-67 has not become established as a 
standard decision-making factor for or against chemotherapy. Re-
cently, several multigene tests, some of which were specifically de-
veloped for hormone receptor-positive patients, were shown to 
identify a subgroup of patients who have such a good prognosis 
that chemotherapy does not appear to be necessary [15–22]. 2 
studies have also prospectively validated the usefulness of these 
tests in treatment algorithms [21, 22]. These studies concluded that 
chemotherapy may be avoided in patients with a specific genomic 
profile – a group that represented 20 and 39%, respectively, of the 
study populations investigated in the TAILORx (Trial Assigning 
IndividuaLized Options for Treatment/Rx) and MINDACT (Mi-
croarray In Node-negative Disease may Avoid ChemoTherapy) 
studies [21, 22].
Neoadjuvant chemotherapy is an excellent in vivo model for as-
sessing both responsiveness to treatment and the effectiveness of 
the treatment [4]. Implementing molecular tests and using clinical 
predictive factors after assessment in the neoadjuvant treatment 
setting can provide additional information about the predictive ca-
pabilities of the tests and factors used. However, neoadjuvant 
chemotherapy is now only rarely administered in hormone recep-
tor-positive patients.
The following 2 issues are important for planning the optimal 
incorporation of multigene assays into clinical practice and clinical 
studies in the neoadjuvant setting: Which hormone receptor-posi-
tive breast cancer patients receive systemic therapy at the time of 
the initial diagnosis? And which patients receive chemotherapy be-
fore surgery (neoadjuvant treatment) and after surgery (adjuvant 
treatment)?
Hence, the aim of this study was to identify patient and tumor 
characteristics that influence treatment decisions for or against 
chemotherapy in a group of postmenopausal patients with hor-
mone receptor-positive tumors, who were included in the EvAlu-
ate-TM study. A further aim was to identify patient and tumor 
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characteristics that determine whether to administer adjuvant or 
neoadjuvant chemotherapy once a decision in favor of chemother-
apy has been made.
Patients and Methods
Description of the EvAluate-TM Study
The EvAluate-TM study is a prospective, multicenter, noninterventional, 
and observational study in which treatment with the aromatase inhibitor letro-
zole was evaluated in postmenopausal women with hormone receptor-positive 
breast cancer [23]. To participate, study sites were required to be a part of or 
associated with a breast cancer center certified by the German Cancer Society 
(Deutsche Krebsgesellschaft e.V.) and the German Society for Breast Diseases 
(Deutsche Gesellschaft für Senologie e.V.) [24]. Approval of the study was ob-
tained from the ethical review committee of the Faculty of Medicine at the Frie-
drich Alexander University of Erlangen-Nuremberg and the relevant ethics 
committees of all the study centers involved. All patients provided written in-
formed consent after receiving detailed instructions and before inclusion in the 
noninterventional study.
Patients
Between April 2008 and April 2009, 5,045 postmenopausal patients at 339 
study sites all over Germany were included in the EvAluate-TM study. A total of 
5,041 hormone receptor-positive patients were documented in the database (ex-
cluding 4 patients). For this analysis, patients were excluded in the following hi-
erarchical order: those with metastatic breast cancer at the time of inclusion (252 
patients); those in whom antihormonal therapy had started more than 1 year 
before study entry (238 patients); those with insufficient data quality regarding 
the start of antihormonal therapy (370 patients); and those who did not com-
plete the patient questionnaire about their satisfaction with the information re-
ceived (257 patients). The final study population thus consisted of 3,924 post-
menopausal patients with primary hormone receptor-positive breast cancer, 
who started adjuvant therapy with letrozole within 1 year.
Data Acquisition
Before the start of therapy, data on patient and tumor characteristics, as well 
as the patients’ medical history, were collected and documented in a remote 
data entry system (using an electronic case report form). Patient information 
included common epidemiological characteristics, concomitant medication, 
and diseases.
Statistical Considerations
Two different binary outcome variables were created. The first (referred to 
as ‘general chemotherapy administration’) distinguished between study partici-
pants who were treated with adjuvant or neoadjuvant chemotherapy on the one 
hand, and patients who did not receive adjuvant or neoadjuvant chemotherapy 
on the other hand. The other binary outcome variable (referred to as ‘type of 
chemotherapy timing’) only described patients who were treated with either ad-
juvant or neoadjuvant chemotherapy, distinguishing between patients who re-
ceived adjuvant chemotherapy on the one hand, and patients who underwent 
neoadjuvant chemotherapy on the other hand.
Patient and tumor characteristics were cross-tabulated with these variables 
and tested for associations using the appropriate chi-squared tests. A logistic 
regression model was also constructed for each outcome variable as a depend-
ent variable. The model was built using all of the following independent varia-
bles: age, body mass index (BMI), number of different co-medications, and 
number of different co-morbidities, as continuous variables; tumor grade as an 
ordinal variable; and HER2 status as a binary variable (positive vs. negative). A 
final model was then built for each model, applying stepwise backward variable 
selection.
All statistical tests were two-sided, and p < 0.05 was regarded as statistically 
significant. Calculations were carried out using IBM SPSS Statistics for Win-
dows, version 21 (IBM Corporation, Armonk, NY, USA).
Results
Patient Characteristics and Univariate Analyses
A total of 3,924 postmenopausal patients with hormone recep-
tor-positive breast cancer who were included in the EvAluate-TM 
study participated in this analysis. Of these, 1,466 (37.4%) patients 
received chemotherapy, either in the neoadjuvant or the adjuvant 
setting. The mean age of the patients enrolled was 65.0 ± 8.3 years, 




Chemotherapy, n (%) p value
no yes
Age, years
<50    93 (100)    32 (34.4)    61 (65.6) <0.001
50–65 1,828 (100)   972 (53.2)   856 (46.8)
>65 1,997 (100) 1,449 (72.6)   548 (27.4)
Total, n 3,918 2,453 1,465
BMI, kg/m²
<20   139 (100)    89 (64.0)    50 (36.0) 0.160
20–25 1,248 (100)   801 (64.2)   447 (35.8)
25–30 1,509 (100)   937 (62.1)   572 (37.9)
>30 1,005 (100)   617 (61.4)   388 (38.6)
Total, n 3,901 2,444 1,457 
ECOG
0 or 1 3,770 (100) 2,356 (62.5) 1,414 (37.5) 0.353
>1   151 (100)   100 (66.2)    51 (33.8)
Total, n 3,921 2,456 1,465
Grading
1   586 (100)   511 (87.2)    75 (12.8) <0.001
2 2,688 (100) 1,711 (63.7)   977 (36.3)
3   623 (100)   221 (35.5)   402 (64.5)
Total, n 3,897 2,443 1,454
HER2 
Negative 3,402 (100) 2,224 (65.4) 1,178 (34.6) <0.001
Positive   491 (100)   208 (42.4)   283 (57.6)
Total, n 3,893 2,432 1,461
Concomitant medication, n
0 1,685 (100)   989 (58.7)   696 (41.3) <0.001
1   605 (100)   378 (62.5)   227 (37.5)
2   431 (100)   274 (63.6)   157 (36.4)
3   281 (100)   165 (58.7)   116 (41.3)
≥4   922 (100)   652 (70.7)   270 (29.3)
Total, n 3,924 2,458 1,466
Concomitant diseases, n
0 1,328 (100) 772 (58.1)   556 (41.9) < 0.001
1 1,059 (100) 647 (61.1)   412 (38.9)
2 745 (100) 483 (64.8)   262 (35.2)
3 426 (100) 290 (68.1)   136 (31.9)
≥4 366 (100) 266 (72.7)   100 (27.3)
Total, n 3,924 2,458 1,466
BMI = Body mass index; ECOG = Eastern Cooperative Oncology Group.
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and their mean BMI was 27.4 ± 5.2 kg/m2. All other tumor charac-
teristics were within the expected ranges and frequencies and are 
shown in table 1. As tumor size and nodal status was only available 
for patients who were not treated neoadjuvantly, data for this 
group of patients is provided in supplementary table 1 (available at 
www.karger.com/?DOI=452468).
General Chemotherapy Use
Patients who received chemotherapy were more than 4 years 
younger than those who did not (62.1 ± 7.3 years vs. 66.7 ± 8.5 
years; p < 0.001). Although 46.8% of all patients aged 50–65 years 
received chemotherapy, only 27.4% of women aged over 65 were 
treated with chemotherapy (table  1). There did not appear to be 
any differences in BMI (27.3 ± 5.1 vs. 27.6 ± 5.3; p = 0.076). The 
molecular parameters of grading and HER2 were clearly associated 
with chemotherapy administration. Although 64.5% of all patients 
with grade 3 tumors received chemotherapy, only 12.8% of those 
with grade 1 tumors had cytotoxic treatment. HER2-positive pa-
tients received chemotherapy in 57.6% of cases and HER2-negative 
patients in 34.6%. All further associations with patient and tumor 
characteristics are shown in table 1.
In the multivariate model, age, BMI, tumor grade, HER2 status, 
and number of concomitant medications remained in the model 
predicting general chemotherapy administration. Younger age, 
higher BMI, higher tumor grade, positive HER2 status, and low co-
medication use were associated with chemotherapy administration 
(table 2). We repeated the analysis after exclusion of neoadjuvantly 
treated patients, this time including tumor stage. Tumor stage and 
nodal status additionally remained in the final model and were as-
sociated with the decision for adjuvant chemotherapy (supplemen-
tary table 2, available at www.karger.com/?DOI=452468).
Neoadjuvant Chemotherapy Administration
Among the group of patients treated with chemotherapy (n = 
1,466), 20% received neoadjuvant chemotherapy (n = 293; 7.5% of 
the complete cohort). The only 2 variables that indicated an asso-
ciation with neoadjuvant rather than adjuvant chemotherapy ad-
ministration were age and BMI. Patients who received neoadjuvant 
treatment were approximately 2.5 years younger than those who 
received adjuvant treatment (60.1 ± 7.5 years vs. 62.6 ± 7.2 years). 
The mean BMI of women who received neoadjuvant treatment was 
26.8 ± 4.8, compared to 27.8 ± 5.4 among those who received adju-
vant treatment. Neoadjuvant therapy was thus used in 13.5% of all 
women who were older than 65 years and in 23.4% of those aged 
50–65 years (table 3). The neoadjuvant chemotherapy rates ranged 
from 24% in women with a BMI < 20 kg/m2 to 17.3% in women 
with a BMI > 30 kg/m2.
Age and BMI were the only 2 variables that persisted in the se-
lection process used in the logistic regression model. They re-
mained as independent predictive factors for the administration of 
neoadjuvant chemotherapy (table 4). 
Discussion
The study showed that approximately 37% of all postmenopau-
sal women with hormone receptor-positive breast cancer received 
adjuvant or neoadjuvant chemotherapy. Of these, 20% received 
neoadjuvant treatment. Age, BMI, tumor grade, and HER2 were 
clearly correlated with chemotherapy administration; age and BMI 
were clearly correlated with the administration of neoadjuvant 
chemotherapy.
When the percentage of chemotherapy utilization in the EvAlu-
ate-TM study is compared with that in large adjuvant aromatase 
inhibitor studies, the rate of chemotherapy in this patient popula-
tion was higher than the rates reported in the ATAC (Arimidex, 
Tamoxifen Alone or in Combination) and Breast International 
Group 1–98 (BIG 1–98) studies (21 and 25%, respectively) [25, 26]. 
However, this figure lies in the range of previous chemotherapy 
rates (32%) reported in the Intergroup Exemestane Study 031 (IES-
031) [27]. This might be due to the fact that initial aromatase in-
hibitor therapy was not regarded as standard for a long time after 
first publications of improved disease-free survival but not overall 
survival for this treatment approach [25, 26]. An overall survival 
benefit was only reported later, in 2011, and only for 1 substance, 
within a specifically applied statistical analysis [28]. This might be 
one reason for the higher percentage of women with an unfavora-
ble prognosis in the EvAluate-TM study. On the other hand, dur-
ing the recruitment period for the large adjuvant aromatase inhibi-
tor studies, trastuzumab had not yet been approved, leading to a 
lower percentage of women receiving chemotherapy among HER2-
positive patients.
Interestingly, only 57.6% of the HER2-positive women were 
treated with adjuvant chemotherapy – meaning that only 57.6% of 
the patients could have been treated with trastuzumab which was 
approved before the start of recruitment for the EvAluate-TM 
study. This closely approximates the percentage of women who 
were reported to have an indication for trastuzumab (52.7%) in a 
study in the Netherlands [29]. While 78.1% of the women in the 
Netherlands study received trastuzumab, about 15% of these 
women had no indication for trastuzumab [29]. The figure of 
57.6% in the present study thus appears plausible.
Table 2. Logistic regression analysis (final model) with significant patient 
and tumor characteristics for predicting the general choice of chemotherapy
Characteristics ORa 95% CI p value
Ageb 0.92 0.91–0.93 < 0.001
BMIb 1.02 1.01–1.04 0.002
Gradingb 3.76 3.20–4.36 < 0.001
HER2
Negative 1.00c
Positive 2.00 1.61–2.49 < 0.001




OR = Odds ratio; CI = confidence interval; BMI = body mass index.
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The rate of chemotherapy administration may have increased 
over time among patients with hormone receptor-positive breast 
cancer [30]. However, information about subgroups of women 
who do not benefit from chemotherapy is now available, and there 
is hence a strong need to identify subgroups in whom toxic chemo-
therapy can be avoided.
Recent reports from prospective randomized trials investigating 
treatment algorithms using multigene prognostic tests [21, 22] ap-
pear to have supplied the information needed to allow these tests to 
be incorporated systematically into healthcare so that unnecessary 
chemotherapy can be avoided among patients with breast cancer. 
Characteristics Total,  
n (%)
Chemotherapy, n (%) p value
neoadjuvant adjuvant
Age, years
<50    61 (100)    19 (31.1)    42 (68.9) < 0.001
50–65   856 (100)   200 (23.4)   656 (76.6)
>65   548 (100)    74 (13.5)   474 (86.5)
Total, n 1,465   293 1,172
BMI, kg/m2
<20    50 (100)    12 (24.0)    38 (76.0) 0.027
20–25   447 (100)   103 (23.0)   344 (77.0)
25–30   572 (100)   109 (19.1)   463 (80.9)
>30   388 (100)    67 (17.3)   321 (82.7)
Total, n 1,457   292 1,166
ECOG
0 or 1 1,414 (100)   281 (19.9) 1,133 (80.1) 0.521
>1    51 (100)    12 (23.5)    39 (76.5)
Total, n 1,465 2,456 1,465
Grading
1    75 (100)    12 (16.0)    63 (84.0) 0.611
2   977 (100)   199 (20.4)   778 (79.6)
3   402 (100)    77 (19.2)   325 (80.8)
Total, n 1,454   288 1,166
HER2 
Negative 1,178 (100)   235 (19.9)   943 (80.1)  0.942
Positive   283 (100)    57 (20.1)   226 (79.9)
Total, n 1,461   292 1,169
Concomitant medication, n
0   696 (100)   139 (20.0)   557 (80.0) 0.438
1   227 (100)    48 (21.1)   179 (78.9)
2   157 (100)    33 (21.0)   124 (79.0)
3   116 (100)    31 (26.7)    85 (73.3)
≥4   270 (100)    42 (15.6)   228 (84.4)
Total, n 1,466   293 1,171
Concomitant diseases, n
0   556 (100)   118 (21.2)   438 (78.8) 0.074
1   412 (100)    91 (22.1)   321 (77.9)
2   262 (100)    47 (17.9)   215 (82.1)
3   136 (100)    18 (13.2)   118 (86.8)
≥4   100 (100)    19 (19.0)    81 (81.0)
Total, n 1,466   293 1,173 (100)
BMI = Body mass index; ECOG = Eastern Cooperative Oncology Group.
Table 3. Patient and tumor characteristics rela-
tive to neoadjuvant or adjuvant chemotherapy sta-
tus in the group of patients receiving chemotherapy
Table 4. Logistic regression analysis (final model) with significant patient 
and tumor characteristics for predicting neoadjuvant or adjuvant chemother-
apy
Characteristics ORa 95% CI p value
Ageb 0.96 0.94–0.94 < 0.001
BMIb 0.97 0.94–0.99 0.017
aAdjusted.
bOR per unit.
OR = Odds ratio; CI = confidence interval; BMI = body mass index.
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There have been several reports on the use of multigene assays in 
clinical practice and on the way in which they can alter treatment 
decisions for or against chemotherapy [30–34]. The results have so 
far been inconsistent, but this may change on the basis of 2 recently 
published randomized studies [21, 22] suggesting that chemother-
apy rates can be reduced by 20 and 29%, respectively. On the basis 
of the data from the EvAluate-TM study, there may be around 
50,000 patients with hormone receptor-positive breast cancer in 
Germany per year [35, 36] – implying an opportunity to reduce 
chemotherapy by about 4,000–8,000 patients per year.
With regard to neoadjuvant chemotherapy, age and BMI were 
the only factors that were predictive for the administration of neo-
adjuvant chemotherapy in the group of patients who received 
chemotherapy. Rates of neoadjuvant chemotherapy vary widely 
within institutions and between countries [37]. In a study in the 
United States, the rate of utilization of neoadjuvant chemotherapy 
was reported to be around 3% [37]. At 7.5%, this figure was more 
than twice as high in the EvAluate-TM study. In both studies, the 
main predictive factor identified was age. In the EvAluate-TM 
study, information about tumor size and nodal status was not 
available at the time of chemotherapy decision-making, while these 
2 variables were also identified as predictors for neoadjuvant 
chemotherapy administration in the study by Onitilo et al. [37]. In-
terestingly, the physicians and patients in the present study did not 
appear to regard co-morbidities and co-medication as reasons for 
not performing neoadjuvant chemotherapy.
This study has several strengths, but also some limitations. It 
needs to be borne in mind that all of the women included in the 
study had been selected for treatment with letrozole as an initial 
therapy. At the time of recruitment for the study, scientific and 
clinical discussions were in progress regarding which patients 
should receive which therapy in relation to tamoxifen, aromatase 
inhibitors, and sequence of administration [38–40]. At that time, 
some held the view that an initial aromatase inhibitor might only 
be necessary in breast cancer patients who had an increased risk of 
recurrence, whereas women with a lower risk of recurrence could 
be treated with tamoxifen followed by an aromatase inhibitor after 
2–3 years. The study population included in the EvAluate-TM 
study might therefore involve some bias in relation to this topic – 
namely, selecting for a group of patients with a greater risk of re-
currence and thus including a higher percentage of women who 
received chemotherapy. Another limitation is the fact that tumor 
size and nodal status had to be excluded from the analysis since 
tumor size was not recorded as the clinical but only the pathologi-
cal tumor size. Tumor size, at the time of decision-making, was 
thus not available in the 20% of patients who received neoadjuvant 
treatment. The same applies to nodal status. In addition, the study 
was conducted in 2008 and 2009. Although it was already known at 
that time that some tumor subtypes, such as tumors with a high 
level of ER expression, benefit less from chemotherapy [9], it can 
be assumed that this information had not yet been incorporated 
into common practice in relation to treatment decision-making. 
One strength of this study is the large sample size and its prospec-
tive nature. It is one of the largest studies concerned with treatment 
management for postmenopausal patients with hormone receptor-
positive breast cancer. Another strength is the broad distribution 
and number of the participating study sites. The study thus pre-
sents an average picture of treatment management in this field 
throughout Germany at the time when it was conducted.
In conclusion, this study provides data on the use of neoadju-
vant and adjuvant chemotherapy in postmenopausal patients with 
hormone receptor-positive early breast cancer. This represents the 
population of breast cancer patients in whom the potential for 
avoiding unnecessary chemotherapy is under discussion. The 
EvAluate-TM study also provides evidence that neoadjuvant 
chemotherapy is commonly performed in this patient population, 
and this should encourage future molecular research in neoadju-
vant chemotherapy trials in this group of patients.
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